Literature DB >> 16700035

Treatment options in lymph node-positive prostate cancer.

Gregory P Swanson1, Ian M Thompson, Joseph Basler.   

Abstract

With improved awareness and screening, the incidence of lymph node-positive prostate cancer has declined dramatically over the last 50 years. Stage of cancer, prostate-specific antigen, and grade are risk factors for positive lymph nodes; and those factors, along with the number of involved lymph nodes, are prognostic factors for outcome. Although the numbers have declined, the number of men with lymph node-positive prostate cancer remains significant, and the current challenge is how best to treat these patients. Commonly used treatments include any combination of androgen ablation, surgery, and radiation. There have been a few studies with chemotherapy, and no treatment has been proven superior to the others. Consequently, there remain several reasonable alternatives to treatment, and long-term survival is not unusual. Copyright 2006 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16700035     DOI: 10.1002/cncr.21947

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Utility of a new bolus-injectable nanoparticle for clinical cancer staging.

Authors:  Mukesh Harisinghani; Robert W Ross; Alexander R Guimaraes; Ralph Weissleder
Journal:  Neoplasia       Date:  2007-12       Impact factor: 5.715

2.  Toxicity and outcome of pelvic IMRT for node-positive prostate cancer.

Authors:  A-C Müller; J Lütjens; M Alber; F Eckert; M Bamberg; D Schilling; C Belka; U Ganswindt
Journal:  Strahlenther Onkol       Date:  2012-10-11       Impact factor: 3.621

Review 3.  Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm.

Authors:  Gilles Créhange; Chien Peter Chen; Charles C Hsu; Norbert Kased; Fergus V Coakley; John Kurhanewicz; Mack Roach
Journal:  Cancer Treat Rev       Date:  2012-06-15       Impact factor: 12.111

4.  The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer.

Authors:  B J Krause; M Souvatzoglou; M Tuncel; K Herrmann; A K Buck; C Praus; T Schuster; H Geinitz; U Treiber; M Schwaiger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-22       Impact factor: 9.236

5.  Biodistributions of 177Lu- and 111In-labeled 7E11 antibodies to prostate-specific membrane antigen in xenograft model of prostate cancer and potential use of 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11 radioimmunotherapy.

Authors:  Mei-Hsiu Pan; Dong-Wei Gao; Jinjin Feng; Jiang He; Youngho Seo; John Tedesco; John G Wolodzko; Bruce H Hasegawa; Benjamin L Franc
Journal:  Mol Imaging Biol       Date:  2008-11-25       Impact factor: 3.488

6.  A retrospective analysis of the prognosis of prostate cancer patients with lymph node involvement on MR lymphography: who might be cured.

Authors:  Hanneke J M Meijer; Oscar A Debats; Emile N J Th van Lin; Johannes Alfred Witjes; Johannes H A M Kaanders; Jelle O Barentsz
Journal:  Radiat Oncol       Date:  2013-07-30       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.